The homozygous type II antithrombin deficient pregnant woman monitored by thrombin generation assay
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F23%3A00013580" target="_blank" >RIV/00023736:_____/23:00013580 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/23:10469882 RIV/00064165:_____/23:10469882
Výsledek na webu
<a href="http://dx.doi.org/10.7754/Clin.Lab.2023.230435" target="_blank" >http://dx.doi.org/10.7754/Clin.Lab.2023.230435</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.7754/Clin.Lab.2023.230435" target="_blank" >10.7754/Clin.Lab.2023.230435</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The homozygous type II antithrombin deficient pregnant woman monitored by thrombin generation assay
Popis výsledku v původním jazyce
We present the case study of a 28-year-old pregnant woman with antithrombin deficiency who was treated with low-molecular-weight heparin (LMWH). Due to severe homozygous type II antithrombin heparin binding site (HBS) deficiency, the thrombin generation (TG) was monitored in this woman via the Thrombin Generation Assay (TGA). We used Siemens diagnostic kits Berichrom® Antithrombin III (IIa) and INNOVANCE® Antithrombin (Xa) to determine antithrombin activity. We used a chromogenic method for determination of factor Xa (FXa) inhibition. There were no thrombotic complications during the whole pregnancy of the observed woman. Antithrombin was administered before and after delivery, which was significantly reflected in the decrease in thrombin generation. Conclusions: Consistent monitoring of thrombin generation with LMWH anticoagulant therapy administration during pregnancy together with antithrombin administration before and after delivery can improve the overall condition of pregnant women and the quality of their care.
Název v anglickém jazyce
The homozygous type II antithrombin deficient pregnant woman monitored by thrombin generation assay
Popis výsledku anglicky
We present the case study of a 28-year-old pregnant woman with antithrombin deficiency who was treated with low-molecular-weight heparin (LMWH). Due to severe homozygous type II antithrombin heparin binding site (HBS) deficiency, the thrombin generation (TG) was monitored in this woman via the Thrombin Generation Assay (TGA). We used Siemens diagnostic kits Berichrom® Antithrombin III (IIa) and INNOVANCE® Antithrombin (Xa) to determine antithrombin activity. We used a chromogenic method for determination of factor Xa (FXa) inhibition. There were no thrombotic complications during the whole pregnancy of the observed woman. Antithrombin was administered before and after delivery, which was significantly reflected in the decrease in thrombin generation. Conclusions: Consistent monitoring of thrombin generation with LMWH anticoagulant therapy administration during pregnancy together with antithrombin administration before and after delivery can improve the overall condition of pregnant women and the quality of their care.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Clinical laboratory
ISSN
1433-6510
e-ISSN
—
Svazek periodika
69
Číslo periodika v rámci svazku
10
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
5
Strana od-do
2171-2175
Kód UT WoS článku
001109223200018
EID výsledku v databázi Scopus
2-s2.0-85175585530